Using genetic testing to identify BRCA mutations in ovarian cancer can help inform the selection of frontline maintenance therapies and manage toxicities.
CU Anschutz
Anschutz Cancer Pavilion
1665 North Aurora Court
2004
Aurora, CO 80045
Genetic Analysis Helps Maximize Clinical Benefit with PARP Inhibitors in BRCA+ Ovarian Cancer
Default sub title
minute read
by OncLive | January 17, 2023
